FinCanna Capital Valuation

Q: What is the Fair Price of 4AL0 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

4AL0 (€0) is trading below our estimate of [[fair value]] (€0.01)

Is 4AL0 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 4AL0 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 4AL0 (€0) is trading below our estimate of fair value (€0.01)

Significantly Below Fair Value: 4AL0 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 4AL0?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for 4AL0. This is calculated by dividing 4AL0's market cap by their current preferred multiple.
What is 4AL0's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	CA$4.98m

4AL0 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	n/a
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does 4AL0's PB Ratio compare to its peers?

The above table shows the PB ratio for 4AL0 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	5.2x
B8FK Biofrontera	0.8x	n/a	€14.1m
SBX SynBiotic	1.9x	107.0%	€29.5m
0RX Redx Pharma	16.6x	-22.3%	€65.0m
HIGH Cantourage Group	1.4x	90.3%	€63.0m
4AL0 FinCanna Capital	n/a	n/a	€5.0m

Price-To-Book vs Peers: 4AL0 has negative equity and a Price-To-Book Ratio (-1.5x) compared to the peer average (5.2x).

Price to Earnings Ratio vs Industry

How does 4AL0's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	19.4%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	19.4%
	n/a	n/a	n/a

No more companies

Price-To-Book vs Industry: 4AL0 has negative equity and a Price-To-Book Ratio (-1.5x) compared to the European Pharmaceuticals industry average (2.4x).

Price to Book Ratio vs Fair Ratio

What is 4AL0's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

4AL0 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	-1.5x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 4AL0's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.